Skip to main content

Physician Search

 


Displaying 1 - 3 of 3

Testing Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases

Breast

This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend the time until the cancer gets worse.
Breast
II
Kennedy, Laura
NCT04647916
SWOGBRES2007

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Multiple Cancer Types

The objective of this study is to evaluate the efficacy and safety of sacituzumab
govitecan-hziy monotherapy and with novel combinations in participants with metastatic
urothelial cancer (mUC).
Bladder, Urologic
II
Davis, Nancy
NCT03547973
VICCURO18120

Strata PATH (Precision Indications for Approved Therapies)

Miscellaneous

StrataPATH is a non-randomized, open-label trial designed to explore efficacy and safety of
multiple FDA-approved and commercially available cancer therapies in new, biomarker-guided
patient populations.
Miscellaneous
II
Berlin, Jordan
NCT05097599
VICCMD2205